Kerala Ayurveda Ltd
NSE: BSE: 530163
₹204.80
(2.55%)
Mon, 25 May 2026, 03:58 am
Market Cap2.66B
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Other
24.5KKerala Ayurveda Analysis
dividend
- Unable to evaluate Kerala Ayurveda's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Kerala Ayurveda's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Kerala Ayurveda is profitable, therefore cash runway is not a concern.
- Kerala Ayurveda is profitable, therefore cash runway is not a concern.
- Kerala Ayurveda had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
- Interest payments on debt are well covered by earnings (EBIT is 3.4x coverage).
- Kerala Ayurveda's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Debt is not well covered by operating cash flow (18.4%, less than 20% of total debt).
- Debt is not covered by short term assets, assets are 0.5x debt.
- Kerala Ayurveda's long term commitments exceed its cash and other short term assets.
- Kerala Ayurveda's level of debt (952.6%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- Anilkumar's remuneration is about average for companies of similar size in India.
- Anilkumar's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Kerala Ayurveda board of directors is less than 3 years, this suggests a new board.
misc
- Kerala Ayurveda is not covered by any analysts.
- Kerala Ayurveda has significant price volatility in the past 3 months.
past
- Kerala Ayurveda's 1-year earnings growth exceeds its 5-year average (83.8% vs 11.2%)
- Kerala Ayurveda's year on year earnings growth rate has been positive over the past 5 years.
- Kerala Ayurveda's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (83.8% vs 22.7%).
- Kerala Ayurveda used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Kerala Ayurveda's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Whilst Kerala Ayurveda made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%), this is metric is skewed due to its high level of debt.
value
- Kerala Ayurveda's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Kerala Ayurveda is good value based on earnings compared to the IN Pharmaceuticals industry average.
- 530163 outperformed the Market in India which returned -14.5% over the past year.
- BSE:530163 is up 53.2% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:530163 is up 53.2% outperforming the market in India which returned 8% over the past month.
- Kerala Ayurveda's share price is below the future cash flow value, but not at a substantial discount (< 40%).
- Kerala Ayurveda is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Kerala Ayurveda is overvalued based on earnings compared to the India market.
- 530163 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Asset Management Companies
Popular Stocks
Indian Indices
Sector Wise Stocks
IPO
Share Market
Best MF Schemes
Platforms
Resources
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800